Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis

Mahajan, Sonia; Prakash, Ajay; Sarma, Phulen; Niraj, Niraj; Bhattacharyya, Anusuya; Medhi, Bikash

doi:10.1016/j.eplepsyres.2022.106895

Cited by 5 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AEs were reported in nearly half the patients included in our study. This proportion was lower than others described [30][31][32]; this result could be due to the relatively lower PER doses used in our patients. However, a recent study, which includes a large number of patients, found similar data to our results [33].…”

Section: Discussioncontrasting

confidence: 87%

Efficacy of Perampanel in Nocturnal Seizures in Adult Patients with Epilepsy

López-Maza,

Gifreu,

Fonseca

et al. 2024

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

Objective. Nocturnal seizures are usually underestimated and represent a major problem in adult patients with epilepsy. Our aim was to study the effectiveness of perampanel for the treatment of nocturnal seizures in adult patients with epilepsy. Methods. Observational study of a prospectively acquired sample of adult patients with focal and generalized epilepsy in which perampanel was started from January to October 2021 in a specialized epilepsy unit in a tertiary hospital. Demographic and clinical characteristics were recorded. All patients completed a follow-up period of at least 3 months. Seizure frequency during the 6-month period before the patient started treatment was obtained from medical records. Retention and responder rates (considered as a nocturnal seizure frequency reduction of ≥50%) and improvement of subjective sleep disturbances were analyzed as outcome measures. Results. Forty-eight patients were included (mean age 39.8±17.4; 60.4% men), and 38 of them had a 6-month follow-up. Focal epilepsy was the most common diagnosis (81.3%), and most patients had a structural etiology (56.3%). Thirty-four (70.8%) patients had drug-resistant epilepsy. The mean nocturnal seizure frequency per month at baseline was 13.2±35.9. Fifteen (31.3%) patients had subjective sleep disturbances at baseline, of which insomnia was the most frequent complaint (16.7%). Perampanel was started at a median dose of 4 mg/day (range=2-14). At 3-month follow-up, the retention rate was 74.6%; 64.6% were considered responders (54.2% were seizure-free). Monthly nocturnal seizures decreased significantly at 3 months (8.2±26.7 vs. 13.2±35.9 seizures/month; p=0.044) and 6 months (5.3±18.2 vs. 13.2±35.9 seizures/month; p=0.006). Subjective sleep disturbances improved at 3-month follow-up (10.4% vs. 31.3%; p=0.002) and 6-month follow-up (10.5% vs. 31.3%; p=0.022). Significance. Perampanel can be a suitable treatment option in adult patients with both focal and generalized epilepsy with nocturnal seizures and can reduce the presence of sleep complaints.

show abstract

Section: Discussioncontrasting

confidence: 87%

Efficacy of Perampanel in Nocturnal Seizures in Adult Patients with Epilepsy

López-Maza,

Gifreu,

Fonseca

et al. 2024

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“… 14 Perampanel has been approved as an effective and safe drug for the treatment of adults and adolescents with drug-resistant epilepsy and there have been no adverse reactions related to sexual function based on post-marketing surveillance. 15 , 16 Lamotrigine has been primarily reported to improve sexual function, particularly in women. 17 , 18 Little information exists on its effects on sexual function in men.…”

Section: Discussionmentioning

confidence: 99%

Lamotrigine induced priapism in children: case analysis and literature review

Cao

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Lamotrigine is an antiepileptic drug that can be used to control many types of seizures as a single-agent or an add-on therapy in patients over 2 years of age. In addition to common adverse reactions, this current case report describes a paediatric male patient with a rare side-effect of persistent penile erectile due to lamotrigine. Previous studies have shown that it can improve sexual function in adult male patients. This patient suffered from refractory epilepsy and pneumonia. He had taken a variety of antiepileptic drugs for a long time and developed priapism after the dosage of lamotrigine had been increased. The priapism improved after drug withdrawal and sedation. Further research is needed to elucidate the mechanism of this rare side-effect.

show abstract